Clinical data | |
---|---|
Trade names | Baciguent, Baciim, others |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Topical, intramuscular, Ophthalmic drug administration |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C66H103N17O16S |
Molar mass | 1422.71 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Bacitracin[1] is a polypeptide antibiotic. It is a mixture of related cyclic peptides produced by Bacillus licheniformis bacteria, that was first isolated from the variety "Tracy I" (ATCC 10716) in 1945.[2] These peptides disrupt Gram-positive bacteria by interfering with cell wall and peptidoglycan synthesis.
Bacitracin is primarily used as a topical preparation, as it can cause kidney damage when used internally.[3] It is generally safe when used topically, but in rare cases may cause hypersensitivity, allergic or anaphylactic reactions, especially in people allergic to neomycin.[4][5]
In 2021, it was the 300th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.[6][7]